SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
作者信息
Casadevall Arturo, Henderson Jeffrey P, Joyner Michael J, Pirofski Liise-Anne
机构信息
Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Departments of Medicine and Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
出版信息
J Clin Invest. 2021 Apr 1;131(7). doi: 10.1172/JCI148832.
Abstract
摘要
相似文献
1
SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
J Clin Invest. 2021 Apr 1;131(7). doi: 10.1172/JCI148832.
2
Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Sci China Life Sci. 2020 Dec;63(12):1833-1849. doi: 10.1007/s11427-020-1859-y. Epub 2020 Dec 1.
3
SARS-CoV-2 evolution during treatment of chronic infection.
Nature. 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y. Epub 2021 Feb 5.
4
Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.
J Clin Invest. 2021 Apr 1;131(7). doi: 10.1172/JCI146927.
5
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
Nature. 2021 May;593(7857):142-146. doi: 10.1038/s41586-021-03471-w. Epub 2021 Mar 29.
6
Neutralizing monoclonal antibodies for treatment of COVID-19.
Nat Rev Immunol. 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x. Epub 2021 Apr 19.
7
Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
Transfus Clin Biol. 2021 Aug;28(3):300-302. doi: 10.1016/j.tracli.2021.05.003. Epub 2021 May 7.
8
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
9
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
10
Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Transfusion. 2021 Jun;61(6):1705-1709. doi: 10.1111/trf.16378. Epub 2021 Mar 22.
引用本文的文献
1
Utility of COVID-19 Seropositive Plasma as Convalescent Plasma: An Immune and Neutralization Antibody Seroprevalence Analysis in Blood Donors for Future Potential Pandemic Readiness.
Cureus. 2024 Mar 28;16(3):e57149. doi: 10.7759/cureus.57149. eCollection 2024 Mar.
2
Re-Emerging COVID-19: Controversy of Its Zoonotic Origin, Risks of Severity of Reinfection and Management.
Int J Gen Med. 2023 Sep 20;16:4307-4319. doi: 10.2147/IJGM.S419789. eCollection 2023.
3
Exercise and Experiments of Nature.
Compr Physiol. 2023 Jun 26;13(3):4879-4907. doi: 10.1002/cphy.c220027.
4
Quantitative Mutation Analysis of Genes and Proteins of Major SARS-CoV-2 Variants of Concern and Interest.
Viruses. 2023 May 18;15(5):1193. doi: 10.3390/v15051193.
5
Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.
J Taibah Univ Med Sci. 2023 Jun;18(3):600-638. doi: 10.1016/j.jtumed.2022.11.007. Epub 2022 Dec 17.
6
Investigation of SARS-CoV-2 Variants and Their Effect on SARS-CoV-2 Monoclonal Antibodies, Convalescent and Vaccine Plasma by a Novel Web Tool.
Diagnostics (Basel). 2022 Nov 19;12(11):2869. doi: 10.3390/diagnostics12112869.
7
COVID-19 convalescent plasma therapy through the lens of the third year of the pandemic.
Clin Microbiol Infect. 2023 Feb;29(2):130-132. doi: 10.1016/j.cmi.2022.10.033. Epub 2022 Nov 4.
8
The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development.
Vaccines (Basel). 2022 Aug 18;10(8):1346. doi: 10.3390/vaccines10081346.
9
and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2.
Pharmaceuticals (Basel). 2022 Apr 25;15(5):530. doi: 10.3390/ph15050530.
10
Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains.
Viruses. 2022 Apr 16;14(4):827. doi: 10.3390/v14040827.
本文引用的文献
1
SARS-CoV-2 Viral Variants-Tackling a Moving Target.
JAMA. 2021 Apr 6;325(13):1261-1262. doi: 10.1001/jama.2021.2088.
2
SARS-CoV-2 evolution during treatment of chronic infection.
Nature. 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y. Epub 2021 Feb 5.
3
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
4
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.
Cell. 2020 Oct 29;183(3):739-751.e8. doi: 10.1016/j.cell.2020.09.032. Epub 2020 Sep 15.
5
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.
Science. 2020 Aug 21;369(6506):1014-1018. doi: 10.1126/science.abd0831. Epub 2020 Jun 15.
6
Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.
Eur J Clin Microbiol Infect Dis. 2017 Feb;36(2):361-371. doi: 10.1007/s10096-016-2809-3. Epub 2016 Nov 15.
7
Palivizumab-resistant human respiratory syncytial virus infection in infancy.
Clin Infect Dis. 2010 Jul 15;51(2):185-8. doi: 10.1086/653534.
8
In vivo selection of respiratory syncytial viruses resistant to palivizumab.
J Virol. 2005 Apr;79(7):3962-8. doi: 10.1128/JVI.79.7.3962-3968.2005.
9
Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.
Virology. 2004 Jan 20;318(2):608-12. doi: 10.1016/j.virol.2003.10.018.
Zotero 插件